NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study ...

NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration with expected once or twice-yearly dosing NPM-139 is a miniature, subdermal implant in ...

The trial has enrolled participants who are intended to be titrated on weekly semaglutide injections for 8 weeks ... is a six-month, subdermal, GLP-1 (exenatide) implant under development for ...

Vivani Medical, Inc. (NASDAQ:VANI) announced the administration of its first GLP-1 (exenatide, NPM-115) implant in the LIBERATE-1 trial in Australia. Vivani's lead program, NPM-115, utilizes a ...

The NPM-115 device is a miniature sub-dermal implant that delivers exenatide ... Participants will first be given injections of Novo Nordisk’s popular GLP-1RA medication Wegovy (semaglutide) for two ...

Vivani's lead program, NPM-115, utilizes a miniature, six-month, subdermal, GLP-1 (exenatide ... intended to be titrated on weekly semaglutide injections for 8 weeks (0.25 mg/week for 4 weeks ...

Vivani Medical, Inc. (VANI), on Wednesday, announced promising preclinical data for its semaglutide implant in development ...

The doc postpones his return to town, examines the ailing wagon boss, and diagnoses him with a subdural hematoma ... Cara enters the room with belly injection number three. The episode thankfully ...

She’ll stand for the injection, and Cara gives it to her ... The doctor believes that Zane has a subdural hematoma, which is now pushing against his brain. They should have done it at the ...